Quality of Reports on Drug Toxicity in Eudravigilance: A Safety Physician's Perspective. [PDF]
Ther Innov Regul SciČendak JB.
europepmc +1 more source
Metabolic Disturbances Associated with Beta-Blocker Therapy: New Insights from a Large-Scale Pharmacovigilance Study. [PDF]
Pharmaceuticals (Basel)Solomon CC +11 more
europepmc +1 more source
Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess. [PDF]
Front PharmacolSauer N +3 more
europepmc +1 more source
Long-term trends in reporting of cardiac adverse drug reactions to COVID-19 vaccines - an exploratory analysis of the EudraVigilance database. [PDF]
BMC Infect DisNazar W +4 more
europepmc +1 more source
From Pharmacovigilance Signals to Mechanistic Phenotypes: Integrating ADMET, PK/PD, and Network Context to Interpret Antiviral Safety in Pregnancy. [PDF]
Pharmaceuticals (Basel)Costa B, Vale N.
europepmc +1 more source
Analysis of drug-drug interactions in spontaneous adverse drug reaction reports from EudraVigilance focusing on psychiatric drugs and somatic medication. [PDF]
BMC PsychiatryDubrall D +5 more
europepmc +1 more source
Signal mining and analysis of adverse events associated with Isotretinoin: A 20-Year real-world pharmacovigilance study based on FAERS and EudraVigilance databases. [PDF]
PLoS OneChen Q +6 more
europepmc +1 more source
Safety profile of fentanyl with different routes of administration: a disproportionality analysis using the EudraVigilance database. [PDF]
Naunyn Schmiedebergs Arch PharmacolDi Napoli R +6 more
europepmc +1 more source
Redundant pharmacovigilance disproportionality analyses: Navigating between Scylla and Charybdis. [PDF]
HeadacheKhouri C +4 more
europepmc +1 more source